# INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
## 8th Edition Staging of Carcinoma of the Oesophagus and Oesophagogastric Junction

### Pathologic Stage Groups
#### pTNM Adenocarcinoma

<table>
<thead>
<tr>
<th>Tis</th>
<th>N0</th>
<th>N1</th>
<th>N2</th>
<th>N3</th>
<th>M1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T1a</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>IA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G2</td>
<td>IB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G3</td>
<td>IC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T1b</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>IB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G3</td>
<td>IC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T2</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>IC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G2</td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G3</td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T3</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IIB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IIB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T4a</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IIB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T4b</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IVA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IVA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Pathologic Stage Groups
#### pTNM Squamous Cell Carcinoma

<table>
<thead>
<tr>
<th>Tis</th>
<th>N0</th>
<th>L</th>
<th>U/M</th>
<th>N1</th>
<th>N2</th>
<th>N3</th>
<th>M1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T1a</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>IA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G2–3</td>
<td>IB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T1b</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>IB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G2–3</td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T2</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G2–3</td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T3</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G2–3</td>
<td>IIB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T4a</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T4b</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IVA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IVA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Postneoadjuvant Pathologic Stage Groups

**ypTNM Adenocarcinoma and Squamous Cell Carcinoma**

<table>
<thead>
<tr>
<th></th>
<th>N0</th>
<th>N1</th>
<th>N2</th>
<th>N3</th>
<th>M1</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>I</td>
<td>IIIA</td>
<td>IIIB</td>
<td>IVA</td>
<td>IVB</td>
</tr>
<tr>
<td>Tis</td>
<td>I</td>
<td>IIIA</td>
<td>IIIB</td>
<td>IVA</td>
<td>IVB</td>
</tr>
<tr>
<td>T1</td>
<td>I</td>
<td>IIIA</td>
<td>IIIB</td>
<td>IVA</td>
<td>IVB</td>
</tr>
<tr>
<td>T2</td>
<td>I</td>
<td>IIIA</td>
<td>IIIB</td>
<td>IVA</td>
<td>IVB</td>
</tr>
<tr>
<td>T3</td>
<td>II</td>
<td>IIIB</td>
<td>IIIB</td>
<td>IVA</td>
<td>IVB</td>
</tr>
<tr>
<td>T4a</td>
<td>IIIB</td>
<td>IVA</td>
<td>IVA</td>
<td>IVA</td>
<td>IVB</td>
</tr>
<tr>
<td>T4b</td>
<td>IVA</td>
<td>IVA</td>
<td>IVA</td>
<td>IVA</td>
<td>IVB</td>
</tr>
</tbody>
</table>


*Courtesy of International Association for the Study of Lung Cancer. Permission must be requested and granted before photocopying or reproducing this material for distribution.*

*Tables. Copyright ©2016 Cleveland Clinic Foundation, courtesy of Thomas W. Rice, MD.*

*This reference card is provided as an educational service of Eli Lilly and Company with the permission of IASLC.*